title: Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
authors: RIMJ Managing Editor.
authors: Mary
authors: M
authors: Korr
mesh_terms: D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D002983:Clinical Competence / Q000592:standards; D002985:Clinical Protocols; D016527:Drug Costs; D055808:Drug Discovery; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000191:economics / Q000627:therapeutic use; D015995:Prevalence; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines
chemical_list: D000998:Antiviral Agents; D014761:Viral Hepatitis Vaccines; D012254:Ribavirin; D007372:Interferons